On the stock market since 1992, it operates in the world of health and science. It has 76 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 22% below its peak. The market has trimmed its expectations for the company.
There is $1.8M in the vault; even if every debt were paid off, $1.0M would remain.
Over the last 12 months, company executives reported 17 buys and 5 sells. Management buying with its own money is usually read as a good sign.
A loss of $0 against $0 in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
On our five-subject report card, PEYE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PEYE is a high-risk stock — not yet profitable, and its future rides on its product catching on.